Does vitamin E supplementation prevent heart disease?
Weak EvidenceNO
Weak evidence against vitamin E for heart disease prevention. Despite promising observational data and biological plausibility, large RCTs (HOPE, ATBC, SELECT) consistently show no cardiovascular benefit from vitamin E supplementation. Some meta-analyses suggest high doses may slightly increase all-cause mortality.
The Verdict
Weak evidence against vitamin E for heart disease prevention. Despite promising observational data and biological plausibility, large RCTs (HOPE, ATBC, SELECT) consistently show no cardiovascular benefit from vitamin E supplementation. Some meta-analyses suggest high doses may slightly increase all-cause mortality.
What the Evidence Shows
Vitamin E supplementation for cardiovascular protection represents one of the most prominent failures of the antioxidant hypothesis in medicine. The rationale was compelling: oxidized LDL drives atherosclerosis, vitamin E (alpha-tocopherol) is the primary lipid-soluble antioxidant, and observational studies in the 1990s showed 30-40% lower CVD risk among vitamin E supplement users. However, large randomized controlled trials systematically failed to confirm these benefits. The HOPE trial (9,541 patients, 4.5 years) found no reduction in cardiovascular events with 400 IU/day. The ATBC trial found no benefit and suggested increased hemorrhagic stroke risk. The Women's Health Study (39,876 women, 10 years) found no cardiovascular benefit from 600 IU every other day. The SELECT trial was stopped early due to futility and a signal of increased prostate cancer risk. A 2005 meta-analysis by Miller et al. suggested doses above 400 IU/day might increase all-cause mortality, though this analysis was contested methodologically. The disconnect between observational and trial data likely reflects healthy-user bias (supplement users have overall healthier lifestyles) and the difference between dietary antioxidants in food matrices versus isolated high-dose supplements. Current guidelines from the AHA and ACC do not recommend vitamin E supplementation for cardiovascular prevention, and the USPSTF has issued a statement against its use for this purpose.
Evidence Quality
5
Meta-Analyses
10
RCTs
15
Observational
Important Caveats
- ⚠️ Observational data was promising but completely contradicted by randomized trials
- ⚠️ The failure illustrates healthy-user bias in supplement observational research
- ⚠️ High doses (>400 IU/day) may slightly increase all-cause mortality
- ⚠️ Dietary vitamin E from food sources may behave differently than supplements
- ⚠️ The full vitamin E complex (mixed tocopherols and tocotrienols) is poorly studied compared to alpha-tocopherol alone
Population Studied
Adults at high cardiovascular risk, healthy adults for primary prevention; mega-trials enrolled 10,000-40,000 participants followed for 4-10 years
Dosage
Most trials used 400-800 IU/day of synthetic dl-alpha-tocopherol or natural d-alpha-tocopherol; dietary intake is typically 15-30 IU/day
Duration
Major trials lasted 4-10 years with adequate follow-up for cardiovascular events; no benefit at any time point
Supporting Studies (2)
Vitamin E consumption and the risk of coronary heart disease in men
ObservationalRimm EB, Stampfer MJ, Ascherio A, et al. · New England Journal of Medicine (1993)
In the Health Professionals Follow-Up Study (39,910 men, 4 years), those taking vitamin E supplements (>60 IU/day) had 36% lower risk of coronary heart disease compared to non-users.
View paper (DOI) →Vitamin E in the primary prevention of cardiovascular disease: the Women's Health Study
RCTLee IM, Cook NR, Gaziano JM, et al. · JAMA (2005)
Among 39,876 women followed for 10 years, vitamin E (600 IU every other day) showed a non-significant 7% reduction in major cardiovascular events but a significant 24% reduction in cardiovascular death (secondary endpoint).
View paper (DOI) →Contradicting Studies (2)
Vitamin E supplementation and cardiovascular events in high-risk patients: the HOPE trial
RCTYusuf S, Dagenais G, Pogue J, et al. · New England Journal of Medicine (2000)
In 9,541 patients at high cardiovascular risk followed for 4.5 years, vitamin E (400 IU/day) showed no reduction in cardiovascular events (RR 1.05, 95% CI 0.95-1.16), heart attacks, strokes, or cardiovascular death compared to placebo.
Why this disagrees:
The largest and most rigorous trial in high-risk patients found absolutely no cardiovascular benefit from vitamin E, definitively contradicting the antioxidant hypothesis for heart disease prevention with isolated supplements.
Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality
Meta-AnalysisMiller ER, Pastor-Barriuso R, Dalal D, et al. · Annals of Internal Medicine (2005)
Meta-analysis of 19 RCTs (135,967 participants) found that vitamin E doses of 400 IU/day or higher were associated with a small but significant increase in all-cause mortality (RR 1.04, p=0.035), suggesting potential harm from high-dose supplementation.
Why this disagrees:
Not only does vitamin E fail to prevent heart disease, but high-dose supplementation may actually increase overall mortality, making it one of the clearest examples of a supplement that moved from promising to contraindicated based on RCT evidence.
Related Claims
Does CoQ10 improve heart health?
Moderate EvidenceModerate evidence supports CoQ10 supplementation for heart failure patients, with the Q-SYMBIO trial showing reduced cardiovascular mortality. Evidence for prevention in healthy individuals is weaker, and benefits for statin-related muscle pain are inconsistent.
Does high-dose vitamin C fight cancer?
Weak EvidenceWeak evidence supports high-dose vitamin C as a cancer treatment. Intravenous (IV) vitamin C shows some anticancer activity in preclinical models and early-phase trials, but large RCTs of oral vitamin C found no survival benefit. IV vitamin C may improve quality of life in advanced cancer but is not a proven anti-tumor therapy.
Does omega-3 supplementation reduce inflammation?
Strong EvidenceStrong evidence shows omega-3 fatty acids (EPA and DHA) reduce inflammatory markers, particularly C-reactive protein and IL-6. Effects are most pronounced in people with elevated baseline inflammation.